GlassScriptPhysician profile
Carrie Ly Thonen
NPI 1730299504
$2,776.64
in general payments reported to CMS, 2019-2025
30 companies · $656 in 2025
The $656 reported for 2025 was more than what 91% of Women'S Health (Nurse Practitioner) providers received nationally (typical 2025 total: $123).
See the full distribution for Women's Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $481 · 2022: $595 · 2023: $579 · 2024: $466 · 2025: $656.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,700.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,700.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $529.51 | 2023-2025 | Gemtesa, Myfembree |
| Axonics, INC. | $328.06 | 2021-2024 | Axonics |
| Astellas Pharma US INC | $286.28 | 2022-2025 | Veozah, Myrbetriq |
| Mayne Pharma Commercial LLC | $223.01 | 2023-2025 | |
| Evofem Biosciences, INC. | $207.10 | 2021 | |
| Myovant Sciences INC. | $125.00 | 2022 | |
| Shield Therapeutics INC | $101.88 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $95.15 | 2022 | |
| Biogen, INC. | $71.85 | 2025 | Zurzuvae |
| Novo Nordisk INC | $68.19 | 2023 | Wegovy |
| Amgen INC. | $63.56 | 2021-2024 | Otezla |
| Scynexis, INC. | $59.77 | 2022 | |
| Abbvie INC. | $59.42 | 2022-2025 | |
| Medtronic, INC. | $52.01 | 2022-2025 | Interstim |
| Dentsply Ih Ab | $49.25 | 2023-2024 | Lofric, Lofric |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $46.10 | 2021-2023 | |
| Urovant Sciences INC | $45.80 | 2022 | |
| Hologic Sales and Service, LLC | $42.85 | 2023-2024 | Aptima |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.45 | 2022 | |
| Merck Sharp & Dohme LLC | $35.28 | 2021-2023 | Keytruda |
| Biohaven Pharmaceutical Holding Company LTD. | $33.54 | 2022 | |
| Exeltis, USA INC. | $32.95 | 2022-2025 | Slynd |
| Boston Scientific Corporation | $30.24 | 2022-2025 | Axonics |
| Coloplast Corp | $30.17 | 2021 | |
| Laborie Medical Technologies Corp. | $30.12 | 2021 | |
| 180 Medical, INC. | $26.77 | 2025 | |
| Avion Pharmaceuticals | $17.83 | 2022 | |
| Radiometer America, INC | $16.87 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.77 | 2021 | |
| Organon LLC | $13.86 | 2023 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carrie Thonen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.